Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2024
+7 (495) 482-43-29
EN
0 ₽
0 products
All journals
Journal
Year
Year
Search result: 0

I.V. Sarvilina

Medical Center «Novomedicina» LLC

Al.B. Danilov

Sechenov First Moscow State Medical University (Sechenov University)

O.N. Tkacheva

Pirogov Russian National Research Medical University

O.A. Gromova

Federal Research Center «Computer Science and Control»

E.Yu. Solovieva

Pirogov Russian National Research Medical University

E.N. Dudinskaya

Russian Clinical and Research Center of Gerontology — Pirogov Russian National Research Medical University

A.V. Rozanov

Russian Clinical and Research Center of Gerontology — Pirogov Russian National Research Medical University

E.A. Kartashova

Rostov State Medical University

Influence of chronic pain in osteoarthritis on the risk of cardiovascular diseases and modern methods of drug prevention

Authors:

I.V. Sarvilina, Al.B. Danilov, O.N. Tkacheva, O.A. Gromova, E.Yu. Solovieva, E.N. Dudinskaya, A.V. Rozanov, E.A. Kartashova

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(5): 20‑30

DOI: 10.17116/jnevro202312305120

Views: 1526

Downloaded: 3

Buy for 200₽
Contact the author
Table of contents

INFLUENCE OF CHRONIC PAIN IN OSTEOARTHRITIS ON THE RISK OF CARDIOVASCULAR DISEASES AND MODERN METHODS OF DRUG PREVENTION
INFLUENCE OF CHRONIC PAIN IN OSTEOARTHRITIS ON THE RISK OF CARDIOVASCULAR DISEASES AND MODERN METHODS OF DRUG PREVENTION

To cite this article:

Sarvilina IV, Danilov AlB, Tkacheva ON, Gromova OA, Solovieva EYu, Dudinskaya EN, Rozanov AV, Kartashova EA. Influence of chronic pain in osteoarthritis on the risk of cardiovascular diseases and modern methods of drug prevention. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(5):20‑30. (In Russ.)
https://doi.org/10.17116/jnevro202312305120

Здоровье щитовидной железы – 2024
Перекрестки терапевтических проблем
Доказательная гастроэнтерология: pro et contra
Актуальные вопросы педиатрической практики
Подписка 2024, 2 полугодие
NN - давайте знакомится (08.04.2024)
Использование инфографики авторами научных работ
МСФ на ЯМ
Mediasphera_Net
1med.tv
Close metadata
Recommended articles:
The use of a fixed combination of diclofenac and orphenadrine in the treatment of acute pain syndrome in patients with discogenic lumbosacral radi­culopathy and lumboischialgia. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(3):122-129
A complex of B vita­mins, choline and inosine in the treatment of chro­nic pain. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;(4):114-119
Peri­pheral noci­ceptive mechanisms — targets for local painkillers. Russian Journal of Pain. 2023;(1):52-59
Cata­strophizing and chro­nic pain: a modern view on the problem. Russian Journal of Pain. 2023;(1):60-72
MicroRNA-34a in cardiovascular disease: a glimpse into the future. Russian Cardiology Bulletin. 2023;(1):14-22
Comparison of ct angiography and scoring systems for cardiovascular risk stra­tification in asymptomatic patients. Russian Journal of Cardiology and Cardiovascular Surgery. 2023;(2):190-198
Imme­diate resu­lts of intrathoracic inno­minate artery reco­nstructions. Russian Journal of Cardiology and Cardiovascular Surgery. 2023;(2):217-222
Athe­rosclerosis of caro­tid and lower extremity arte­ries in patients 40—64 years of age with different cardiovascular risk status. Russian Journal of Preventive Medi­cine. 2023;(4):34-42
Ankle distraction hinged motion arthroplasty in the Ilizarov frame. Piro­gov Russian Journal of Surgery. 2023;(5):65-71
Influence of gut microbiota on chro­nic pain syndrome. Russian Journal of Pain. 2023;(2):50-56

The purpose of the review of scientific medical literature was to evaluate the data of the epidemiology of osteoarthritis (OA) and cardiovascular diseases (CVD) with the analysis of risk factors, pathophysiological and pathobiochemical mechanisms of the relationship between OA and the risk of developing CVD in the presence of chronic pain, modern strategies for screening and management of this cohort of patients, the mechanism of action and pharmacological effects of chondroitin sulfate (CS). Conclusions were drawn about the need for additional clinical and observational studies of the efficacy and safety of the parenteral form of CS (Chondroguard) in patients with chronic pain in OA and CVD, improvement of clinical recommendations for the treatment of chronic pain in patients with OA and cardiovascular risk, with special attention to interventions that eliminate mobility restrictions in patients and the inclusion of basic and adjuvant therapy with DMOADs to achieve the goals of multipurpose monotherapy in patients with contraindications to standard therapy drugs.

Keywords:

chronic pain
dorsalgia
osteoarthritis
cardiovascular risk
atherosclerosis
thromboembolism
chondroitin sulfate

Authors:

I.V. Sarvilina

Medical Center «Novomedicina» LLC

Al.B. Danilov

Sechenov First Moscow State Medical University (Sechenov University)

O.N. Tkacheva

Pirogov Russian National Research Medical University

O.A. Gromova

Federal Research Center «Computer Science and Control»

E.Yu. Solovieva

Pirogov Russian National Research Medical University

E.N. Dudinskaya

Russian Clinical and Research Center of Gerontology — Pirogov Russian National Research Medical University

A.V. Rozanov

Russian Clinical and Research Center of Gerontology — Pirogov Russian National Research Medical University

E.A. Kartashova

Rostov State Medical University

Received:

03.05.2023

Accepted:

11.05.2023

List of references:

  1. Cross M, Smith E, Hoy D, et al. The global burden of hip and knee osteoarthritis: Estimates from the global burden of disease 2010 study. Annals of the Rheum Dis. 2014;73(7):1323-1330. https://doi.org/10.1136/annrheumdis-2013-204763
  2. Roth G, Johnson C, Abajobir A, et al. Global regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1-25.  https://doi.org/10.1016/j.jacc.2017.04.052
  3. Mortality GBD, Causes of Death C. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117-171.  https://doi.org/10.1016/S0140-6736(14)61682-2
  4. Ryan C, McDonough S, Kirwan J, et al. An investigation of association between chronic musculoskeletal pain and cardiovascular disease in the Health Survey for England (2008). Eur J Pain.2014;18(5):740-750.  https://doi.org/10.1002/j.1532-2149.2013.00405.x
  5. Goodson N, Smith B, Hocking L, et al. Cardiovascular risk factors associated with the metabolic syndrome are more prevalent in people reporting chronic pain: Results from a cross-sectional general population study. Pain. 2013;154:1595-1602. https://doi.org/10.1016/j.pain.2013.04.043
  6. Kerkhoff A, Moreira L, Fuchs F, et al. Association between hypertension and musculoskeletal complaints: A population-based study. J. Hypertens. 2012;30(11):2112-2117. https://doi.org/10.1097/HJH.0b013e3283588268
  7. Rahman M, Kopec J, Anis A, et al. Risk of cardiovascular disease in patients with osteoarthritis: A prospective longitudinal study. Arthritis Care Res. 2013;65(12):1951-1958. https://doi.org/10.1002/acr.22092
  8. Wang H, Bai J, He B, et al. Osteoarthritis and the risk of cardiovascular disease: A meta-analysis of observational studies. Sci Rep. 2016;6:39672. https://doi.org/10.1038/srep39672
  9. Williams A, Kamper S, Wiggers J, et al. Musculoskeletal conditions may increase the risk of chronic disease: A systematic review and meta-analysis of cohort studies. BMC Med. 2018;16(1):167.  https://doi.org/10.1186/s12916-018-1151-2
  10. Provan S, Rollefstad S, Ikdahl E, et al. Biomarkers of cardiovascular risk across phenotypes of osteoarthritis. BMC Rheumatol. 2019;3:33.  https://doi.org/10.1186/s41927-019-0081-8
  11. Barbour K, Boring M, Helmick C, et al. Prevalence of severe joint pain among adults with doctor-diagnosed arthritis — United States, 2002-2014. Morbidity and Mortality Weekly Report. 2016;65(39):1052-1056. https://doi.org/10.15585/mmwr.mm6539a2
  12. Arthritis Foundation. Osteoarthritis May Raise Heart Disease Risk. Retrieved from https://www.arthritis.org/living-with-arthritis/comorbidities/heart-disease/osteoarthritis-ups-cvd-risk.php
  13. Hall A, Stubbs B, Mamas M, et al. Association between osteoarthritis and cardiovascular disease: Systematic review and meta-analysis. Eur J Prev Cardiol. 2016;23(9):938-946.  https://doi.org/10.1177/2047487315610663
  14. Hsu P, Lin H, Li C, Chung W. Increased risk of stroke in patients with osteoarthritis: A population-based cohort study. Osteoarth Cart. 2017;25(7):1026-1031. https://doi.org/10.1016/j.joca.2016.10.027
  15. Baudart P, Louati K, Marcelli C, et al. Association between osteoarthritis and dyslipidaemia: a systematic literature review and meta-analysis. RMD Open. 2017;1:3(2):e00044. https://doi.org/10.1136/rmdopen-2017-000442
  16. Louati K, Vidal C, Berenbaum F, Sellam J. Association between diabetes mellitus and osteoarthritis: systematic literature review and meta-analysis. RMD Open. 2015;1:1(1):e000077. https://doi.org/10.1136/rmdopen-2015-000077
  17. Singh G, Miller J, Lee F, et al. Prevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the Third National Health and Nutrition Examination Survey. Population. 2002;7:17. 
  18. Bijlsma J, Berenbaum F, Lafeber F. Osteoarthritis: an update with relevance for clinical practice. Lancet. 2011;377(9783):2115-2126. https://doi.org/10.1016/S0140-6736(11)60243-2
  19. Zeng C, Bennell K, Yang Z, et al. Risk of venous thromboembolism in knee, hip and hand osteoarthritis: A general population-based cohort study. Ann Rheum Dis. 2020;79(12):1616-1624. https://doi.org/10.1136/annrheumdis-2020-217782
  20. Booker SQ, Content VG. Chronic Pain, Cardiovascular Health, and Related Medication Use in Aging African Americans with Osteoarthritis. J Clin. Nurs. 2020;29(13-14):2675-2690. https://doi.org/10.1111/jocn.15292
  21. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study. Lancet. 2018;392(10159):1789-858.  https://doi.org/10.1016/S0140-6736(18)32279-7
  22. Hunter D, March L, Chew M. Osteoarthritis in 2020 and beyond: a Lancet Commission. Lancet. 2020;396(10264):1711-1712. https://doi.org/10.1016/S0140-6736(20)32230-3
  23. Vos T, Flaxman A, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163-2196. https://doi.org/10.1016/S0140-6736(12)61729-2
  24. Green G. Understanding NSAIDs: from aspirin to COX-2. Clin Corn. 2001;3(5):50-60.  https://doi.org/10.1016/s1098-3597(01)90069-9
  25. Galushko EA, Erdes ShF, Alekseeva LI. Osteoarthrosis in outpatient practice. Sovremennaya revmatologiya. 2012;6(4):66-70. (In Russ.). https://doi.org/10.14412/1996-7012-2012-766
  26. Turkiewicz A, Petersson I, Björk J, et al. Current and future impact of osteoarthritis on health care: A population-based study with projections to year 2032. Osteoarth Cart. 2014;22(11):1826-1832. https://doi.org/10.1016/j.joca.2014.07.015
  27. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-1222. https://doi.org/10.1016/S0140-6736(20)30925-9
  28. van der Burg L, Boonen A, van Amelsvoort L, et al. Effects of cardiovascular comorbidities on work participation in rheumatic diseases: A prospective cohort study among working individuals. Arthritis Care Res. 2014;66(1):157-163.  https://doi.org/10.1002/acr.22095
  29. Ha I, Lee J, Kim M, Kim H, et al. The association between the history of cardiovascular diseases and chronic low back pain in South Koreans: A cross-sectional study. PLoS One. 2014;9(4):e9367. https://doi.org/10.1371/journal.pone.0093671
  30. Vogt M, Nevitt M, Cauley J. Back Problems and Atherosclerosis. Pittsburgh: Lippincott-Raven. 1997.
  31. Von Korff M, Crane P, Lane M, et al. Chronic spinal pain and physical-mental comorbidity in the United States: Results from the national comorbidity survey replication. Pain. 2005;113(3):331-339.  https://doi.org/10.1016/j.pain.2004.11.010
  32. Andersson H. Increased mortality among individuals with chronic widespread pain relates to lifestyle factors: a prospective population-based study. Disabil Rehabil. 2009;31(24):1980-1987. https://doi.org/10.3109/09638280902874154
  33. Bruehl S, Ok Y, Jirjis J, Biridepalli S. Prevalence of clinical hypertension in patients with chronic pain compared to nonpain general medical patients. Clin J Pain. 2005;21(2):147-153.  https://doi.org/10.1097/00002508-200503000-00006
  34. Alan F, Ayis S, Panesar S, Langford R, Donaldson L. Assessing the relationship between chronic pain and cardiovascular disease: A systematic review and meta-analysis. Scand J Pain. 2016;13:76-90.  https://doi.org/10.1016/j.sjpain.2016.06.005
  35. Jonsson H, Helgadottir GP, Aspelund T, et al. Hand osteoarthritis in older women is associated with carotid and coronary atherosclerosis: the AGES Reykjavik study. Ann Rheum Dis. 2009;68(11):1696-1700. https://doi.org/10.1136/ard.2008.096289
  36. Haugen IK, Ramachandran VS, Misra D, et al. Hand osteoarthritis in relation to mortality and incidence of cardiovascular disease: data from the Framingham heart study. Ann Rheum Dis. 2015;74(1):74-81.  https://doi.org/10.1136/annrheumdis-2013-203789
  37. Hoeven TA, Leening MJ, Bindels PJ, et al. Disability and not osteoarthritis predicts cardiovascular disease: a prospective population-based cohort study. Ann Rheum Dis. 2015;74(4):752-756.  https://doi.org/10.1136/annrheumdis-2013-204388
  38. Ong K, Wu B, Cheung B, et al. Arthritis: its prevalence, risk factors, and association with cardiovascular diseases in the United States, 1999 to 2008. Ann Epidemiol. 2013;23(2):80-86.  https://doi.org/10.1016/j.annepidem.2012.11.008
  39. Kadam U, Jordan K, Croft P. Clinical comorbidity in patients with osteoarthritis: a case-control study of general practice consulters in England and Wales. Ann Rheum Dis. 2004;63(4):408-414.  https://doi.org/10.1136/ard.2003.007526
  40. Nuesch E, Dieppe P, Reichenbach S, et al. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ. 2011;342:d1165. https://doi.org/10.1136/bmj.d1165
  41. Rahman M, Kopec J, Cibere J, et al. The relationship between osteoarthritis and cardiovascular disease in a population health survey: a cross-sectional study. BMJ Open. 2013;3(5):e002624. https://doi.org/10.1136/bmjopen-2013-002624
  42. Turkiewicz A, Neogi T, Bjork J, et al. All-cause mortality in knee and hip osteoarthritis and rheumatoid arthritis. Epidemiol. 2016;27(4):479-485.  https://doi.org/10.1097/EDE.0000000000000477
  43. Hochberg M. Mortality in osteoarthritis. Clin Exp Rheumatol. 2008;26(5 Suppl 51):S120-S124.
  44. Barbour K, Lui L-Y, Nevitt M, et al. Hip osteoarthritis and the risk of all-cause and disease-specific mortality in older women: population-based cohort study. Art Rheumatol. 2015;67(7):1798-1805. https://doi.org/10.1002/art.39113
  45. Haara M, Manninen P, Kroger H, et al. Osteoarthritis of finger joints in Finns aged 30 or over: prevalence, determinants, and association with mortality. Ann Rheum Dis. 2003;62(2):151-158.  https://doi.org/10.1136/ard.62.2.151
  46. Xing D, Xu Y, Liu Q, et al. Osteoarthritis and all-cause mortality in worldwide populations: grading the evidence from a meta-analysis. Sci Rep. 2016;18;6:24393. https://doi.org/10.1038/srep24393
  47. Hawker G, Croxford R, Bierman A, et al. All-cause mortality and serious cardiovascular events in people with hip and knee osteoarthritis: a popula tion based cohort study. PLoS One. 2014;9(3):e91286. https://doi.org/10.1371/journal.pone.0091286
  48. Turkiewicz A, Kiadaliri F, Englund M. Cause-specific mortality in osteoarthritis of peripheral joints. Osteoarthritis Cart. 2019;27(6):848-854.  https://doi.org/10.1016/j.joca.2019.02.793
  49. Huang X, Wilkie R, Mamas MYuD. Prevalence of Cardiovascular Risk Factors in Osteoarthritis Patients Derived from Primary Care Records: A Systematic Review of Observational Studies. J Diabetes Clin Res. 2021;3(3):68-77.  https://doi.org/10.33696/diabetes.3.042
  50. Goel S, Kamath S, Annappa R, et al. Cross-sectional assessment of cardiovascular risk factors in patients with knee osteoarthritis. Ann Rheum Dis. 2004;63(3):144-149. 
  51. Macêdo M, Santos V, Pereira R, Fuller R. Association between osteoarthritis and atherosclerosis: A systematic review and meta-analysis. Exp Gerontol. 2022;161:111734. https://doi.org/10.1016/j.exger.2022.111734
  52. Park D, Park Y, Ko S, et al. Association between knee osteoarthritis and the risk of cardiovascular disease and the synergistic adverse efects of lack of exercise. Nature Sci Rep. 2023;13(1):2777. https://doi.org/10.1038/s41598-023-29581-1
  53. Wang Sh, Liu Y, Wu K, et al. Osteoarthritis and risk of cardiovascular diseases: A Mendelian randomization study. Injury. 2023;S0020-1383(23)00282-6.  https://doi.org/10.1016/j.injury.2023.03.026
  54. Oliveira C, Maher C, Franco M, et al. Co-occurrence of Chronic Musculoskeletal Pain and Cardiovascular Diseases: A Systematic Review with Meta-analysis. Pain Med. 2020;21:1106-1121. https://doi.org/10.1093/pm/pnz217
  55. Macfarlane G, Barnish M, Jones G. Persons with chronic widespread pain experience excess mortality: Longitudinal results from UK Biobank and meta-analysis. Ann Rheum Dis. 2017;76:1815-1822. https://doi.org/10.1136/annrheumdis-2017-211476
  56. Holmberg T, Davidsen M, Thygesen L, et al. Mortality among persons experiencing musculoskeletal pain: A prospective study among Danish men and women. BMC Musculoskelet Disord. 2020;21(8):666-669.  https://doi.org/10.1186/s12891-020-03620-8
  57. Tesarz J, Eich W, Baumeister D, et al. Widespread pain is a risk factor for cardiovascular mortality: Results from the Framingham Heart Study. Eur Heart J. 2019;40(9):1609-1617. https://doi.org/10.1093/eurheartj/ehz111
  58. Rodríguez-Sánchez I, Ortolá R, Graciani A, et al. Pain characteristics, cardiovascular risk factors, and cardiovascular disease. J Gerontol 2022;77(1):204-213.  https://doi.org/10.1093/gerona/glab079
  59. Kendzerska T, Jüni P, King L, et al. The longitudinal relationship between hand, hip and knee osteoarthritis and cardiovascular events: A population-based cohort study. Osteoarthr Cartil. 2017;25(11):1771-1780. https://doi.org/10.1016/j.joca.2017.07.024
  60. Atiquzzaman M, Karim M, Kopec J, et al. Role of nonsteroidal antiinflammatory drugs in the association between osteoarthritis and cardiovascular diseases: A longitudinal study. Arth Rheumatol. 2019;71(11):1835-1843. https://doi.org/10.1002/art.41027
  61. Rönnegård A-S, Nowak C, Äng B, Ärnlöv J. The association between short-term, chronic localized and chronic widespread pain and risk for cardiovascular disease in the UK Biobank. Eur J Prev Cardiol. 2022;29(15):1994-2002. https://doi.org/10.1093/eurjpc/zwac127
  62. Johnston M, Crilly M, Black C, et al. Defining and measuring multimorbidity: A systematic review of systematic reviews. Eur J Pub Health. 2019;29(1):182-189.  https://doi.org/10.1093/eurpub/cky098
  63. Baker T, Clay O, Johnson-Lawrence V, et al. Association of multiple chronic conditions and pain among older Black and White adults with diabetes mellitus. BMC Geriat. 2017;17(1):255.  https://doi.org/10.1186/s12877-017-0652-8
  64. Singer M, Bulled N, Ostrach B, Mendenhall E. Syndemics and the biosocial conception of health. Lancet. 2017;389(10072):941-950.  https://doi.org/10.1016/S0140-6736(17)30003-X
  65. Puenpatom R, Victor T. Increased prevalence of metabolic syndrome in individuals with osteoarthritis: an analysis of NHANES III data. Postgrad Med. 2009;121:9-20.  https://doi.org/10.3810/pgm.2009.11.2073
  66. Hart D, Doyle D, Spector T. Association between metabolic factors and knee osteoarthritis in women: the Chingford Study. J Rheum. 1995;22(6):1118-1123.
  67. Yusuf E, et al. Association between weight or body mass index and hand osteoarthritis: a systematic review. Ann Rheum Dis. 2010;69(4):761-765.  https://doi.org/10.1136/ard.2008.106930
  68. van Leuven S, Franssen R, Kastelein J, et al. Systemic inflammation as a risk factor for atherothrombosis. Rheumatol (Oxford). 2008;47(1):3-7.  https://doi.org/10.1093/rheumatology/kem202
  69. Li J, Siegrist J. Physical activity and risk of cardiovascular disease—a meta-analysis of prospective cohort studies. Int J Environ Res Public Health. 2012;9(2):391-407.  https://doi.org/10.3390/ijerph9020391
  70. Shiroma E, Lee I. Physical activity and cardiovascular health: lessons learned from epidemiological studies across age, gender, and race/ethnicity. Circulation. 2010;122(7):743-752.  https://doi.org/10.1161/CIRCULATIONAHA.109.914721
  71. Corsi M, Alvarez C, Callahan LF, et al. Contributions of symptomatic osteoarthritis and physical function to incident cardiovascular disease. BMC Musculoskel Dis. 2018;19(1):393.  https://doi.org/10.1186/s12891-018-2311-4
  72. Schieir O, Hogg-Johnson S, Glazier R, Badley E. Sex variations in the effects of arthritis and activity limitation on first heart disease event occurrence in the Canadian general population: results from the longitudinal National Population Health Survey. Arthritis Care Res (Hoboken). 2016;68(6):811-818.  https://doi.org/10.1002/acr.22764
  73. King L, Kendzerska T, Hawker G. The Relationship Between Osteoarthritis and Cardiovascular Disease: Results from a Population-Based Cohort. American College of Rheumatology Annual Scientific Meeting. 2015;67:954. 
  74. Marsico F, Paolillo S, Filardi P. NSAIDs and cardiovascular risk. J Cardiovasc Med. 2017;18(Suppl. 1):e40-e43.  https://doi.org/10.2459/JCM.0000000000000443
  75. Haq I, Murphy E, Dacre J. Osteoarthritis. Postgrad Med J. 2003;79(933):377-383.  https://doi.org/10.1136/pmj.79.933.377
  76. Cheras P, Freemont A, Sikorski J. Intraosseous thrombosis in ischemic necrosis of bone and osteoarthritis. Osteoarth Cart. 1993;1(4):219-232.  https://doi.org/10.1016/s1063-4584(05)80328-0
  77. Iannone F, Lapadula G. Obesity and inflammation targets for OA therapy. Curr Drug Targ. 2010;11(5):586-598.  https://doi.org/10.2174/138945010791011857
  78. Findlay D. Vascular pathology and osteoarthritis. Rheumatol. 2007;46(12):1763-1768. https://doi.org/10.1093/rheumatology/kem191
  79. Saccò M, Meschi M, Regolisti G, et al. The relationship between blood pressure and pain. J Clin Hypert (Greenwich). 2013;15(8):600-605.  https://doi.org/10.1111/jch.12145
  80. Gordon J, Johnson J, Nau S, et al. The role of chronic psychosocial stress in explaining racial differences in stress reactivity and pain sensitivity. Psychosom Med. 2017;79(2):201-212.  https://doi.org/10.1097/PSY.0000000000000385
  81. Alan F, Watt H, Langford R, Donaldson L. The association between chronic pain and cardiac disease: A cross-sectional population study. Clin J Pain. 2016;32(12):1062-1068. https://doi.org/10.1097/AJP.0000000000000359
  82. Lu K, Ma F, Yi D, et al. Molecular signaling in temporomandibular joint osteoarthritis. J Orthop Transl. 2022;32:21-27.  https://doi.org/10.1016/j.jot.2021.07.001
  83. Yao X, Sun K, Yu S, et al. Chondrocyte ferroptosis contribute to the progression of osteoarthritis. J Orthop Transl. 2021;27:33-43.  https://doi.org/10.1016/j.jot.2020.09.006
  84. Salaffi F, Ciapetti A, Carotti M. The sources of pain in osteoarthritis: A pathophysiological review. Reumatismo. 2014;66(1):57-71.  https://doi.org/10.4081/reumatismo.2014.766
  85. Morgan M, Thai J, Nazemian V, et al. Changes to the activity and sensitivity of nerves innervating subchondral bone contribute to pain in late-stage osteoarthritis. Pain. 2022;163(2):390-402.  https://doi.org/10.1097/j.pain.0000000000002355
  86. Zhu S, Zhu J, Zhen G, et al. Subchondral bone osteoclasts induce sensory innervation and osteoarthritis pain. J Clin Investig. 2019;129(3):1076-1093. https://doi.org/10.1172/JCI121561
  87. Hill C, Gale D, Chaisson C, et al. Knee effusions, popliteal cysts, and synovial thickening: Association with knee pain in osteoarthritis. J Rheumatol. 2001;28(6):1330-1337.
  88. Simkin P. Bone pain and pressure in osteoarthritic joints. Novartis Found Symp. 2004;260:179-186; discussion 186-190, 277-279. 
  89. Belluzzi E, Macchi V, Fontanella C, et al. Infrapatellar fat pad gene expression and protein production in patients with and without osteoarthritis. Int J Mol Sci. 2020;21(17):6016. https://doi.org/10.3390/ijms21176016
  90. Bamps D, Vriens J, de Hoon J, Voets T. TRP channel cooperation for nociception: Therapeutic opportunities. Ann Rev Pharmacol Toxicol. 2021;61:655-677.  https://doi.org/10.1146/annurev-pharmtox-010919-023238
  91. Stockl S, Eitner A, Bauer R, et al. Substance P and Alpha-calcitonin gene-related peptide differentially affect human osteoarthritic and healthy chondrocytes. Front Immunol. 2021;12:722884. https://doi.org/10.3389/fimmu.2021.722884
  92. Soni A, Wanigasekera V, Mezue M, et al. Central sensitization in knee osteoarthritis: Relating presurgical brainstem neuroimaging and PainDETECT-based patient stratification to arthroplasty outcome. Arth Rheumatol. 2019;71(4):550-560.  https://doi.org/10.1002/art.40749
  93. Fu K, Robbins S, McDougall J. Osteoarthritis: The genesis of pain. Rheumatol. 2018;57(suppl_4):iv43-iv50. https://doi.org/10.1093/rheumatology/kex419
  94. Eitner A, Hofmann G, Schaible H. Mechanisms of osteoarthritic pain. Studies in humans and experimental models. Front Mol Neurosci. 2017;10:349.  https://doi.org/10.3389/fnmol.2017.00349
  95. Dainese P, Wyngaert K, De Mits S, et al. Association between knee inflammation and knee pain in patients with knee osteoarthritis: A systematic review. Osteoarthr Cartil. 2021;30(4):516-534.  https://doi.org/10.1016/j.joca.2021.12.003
  96. Miller R, Miller R, Malfait A. Osteoarthritis joint pain: The cytokine connection. Cytokine. 2014;70(2):185-193.  https://doi.org/10.1016/j.cyto.2014.06.019
  97. Bjurstrom M, Blennow K, Zetterberg H, et al. Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: Associations with pain severity and central sensitization. Pain Rep. 2022;7(1):e988. https://doi.org/10.1097/PR9.0000000000000988
  98. Ohashi Y, Fukushima K, Uchida K, et al. Adverse effects of higher preoperative pain at rest, a central sensitization-related symptom, on outcomes after total hip arthroplasty in patients with osteoarthritis. J Pain Res. 2021;14:3345-3352. https://doi.org/10.2147/JPR.S322314
  99. Ohashi Y, Uchida K, Fukushima K, et al. NGF expression and elevation in hip osteoarthritis patients with pain and central sensitization. Biomed Res Int. 2021;2021:9212585. Published 2021 Sep 18.  https://doi.org/10.1155/2021/9212585
  100. Skaper S. Nerve growth factor: A neuroimmune crosstalk mediator for all seasons. Immunol. 2017;151(1):1-15.  https://doi.org/10.1111/imm.12717
  101. McNamee K, Burleigh A, Gompels L, et al. Treatment of murine osteoarthritis with TrkAd5 reveals a pivotal role for nerve growth factor in non-inflammatory joint pain. Pain. 2010;149(2):386-392.  https://doi.org/10.1016/j.pain.2010.03.002
  102. Ohashi Y, Uchida K, Fukushima K, et al. Correlation between CD163 expression and resting pain in patients with hip osteoarthritis: Possible contribution of CD163+monocytes/macrophages to pain pathogenesis. J Orthop Res. 2022 Jun;40(6):1365-1374. https://doi.org/10.1002/jor.25157
  103. Dirmeier M, Capellino S, Schubert T, et al. Lower density of synovial nerve fibres positive for calcitonin gene-related peptide relative to substance P in rheumatoid arthritis but not in osteoarthritis. Rheumatol. 2008;47(1):36-40.  https://doi.org/10.1093/rheumatology/kem301
  104. Iyengar S, Ossipov M, Johnson K. The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain. 2017;158(4):543-559.  https://doi.org/10.1097/j.pain.0000000000000831
  105. Levescot A, Chang M, Schnell J, et al. IL-1beta-driven osteoclastogenic Tregs accelerate bone erosion in arthritis. J Clin Investig. 2021;131(18):e141008. https://doi.org/10.1172/JCI141008
  106. Kusakabe T, Sawaji Y, Endo K, et al. DUSP-1 induced by PGE2 and PGE1 attenuates IL-1beta-activated MAPK signaling, leading to suppression of NGF expression in human intervertebral disc cells. Int J Mol Sci. 2021;23(1):371.  https://doi.org/10.3390/ijms23010371
  107. Swanson K, Deng M, Ting J. The NLRP3 inflammasome: Molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19(8):477-489.  https://doi.org/10.1038/s41577-019-0165-0
  108. Liu C, Huang Z, Li X, et al. Upregulation of NLRP3 via STAT3-dependent histone acetylation contributes to painful neuropathy induced by bortezomib. Exp Neurol. 2018;302:104-111.  https://doi.org/10.1016/j.expneurol.2018.01.011
  109. Zhao Y, Yang Z. Effect of Wnt signaling pathway on pathogenesis and intervention of neuropathic pain. Exp Ther Med. 2018;16(4):3082-3088. https://doi.org/10.3892/etm.2018.6512
  110. Zhang Y, Zhao D, Li X, et al. The Wnt/beta-catenin pathway regulated cytokines for pathological neuropathic pain in chronic compression of dorsal root ganglion model. Neural Plast. 2021 Apr 19;2021:6680192. https://doi.org/10.1155/2021/6680192
  111. Tang Y, Chen Y, Liu R, et al. Wnt signaling pathways: A role in pain processing. Neuromolecular Med. 2022;24(3):233-249.  https://doi.org/10.1007/s12017-021-08700-z
  112. Reis D, Ruggiero D, Morrison S. The CI area of the rostral ventrolateral medulla oblongata: A critical brainstem region for control of resting and reflex integration of arterial pressure. Am J Hypertens. 1989;2(12 Pt 2):363S-374S.
  113. Malpas S. Sympathetic nervous system overactivity and its role in the development of cardiovascular disease. Physiol Rev. 2010;90(2):513-557.  https://doi.org/10.1152/physrev.00007.2009
  114. Rozanski A, Blumenthal J, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation. 1999;99(16):2192-2217. https://doi.org/10.1161/01.cir.99.16.2192
  115. Hjemdahl P, Larsson P, Wallen N. Effects of stress and beta-blockade on platelet function. Circulation. 1991;84(6 Suppl):VI44-VI61.
  116. Craig A. Pain mechanisms: Labeled lines versus convergence in central processing. Ann Rev Neurosci. 2003;26:1-30.  https://doi.org/10.1146/annurev.neuro.26.041002.131022
  117. Bushnell M, Duncan G, Hofbauer R, et al. Pain perception: Is there a role for primary somatosensory cortex? Proc Natl Acad Sci USA. 1999;96(14):7705-7709. https://doi.org/10.1073/pnas.96.14.7705
  118. Coghill R, Sang C, Maisog J, Iadarola M. Pain intensity processing within the human brain: A bilateral, distributed mechanism. J Neurophysiol. 1999;82(4):1934-1943. https://doi.org/10.1152/jn.1999.82.4.1934
  119. Browne T, Hughes D, Dayas C, et al. Projection neuron axon collaterals in the dorsal horn: Placing a new player in spinal cord pain processing. Front Physiol. 2020;11:560802. https://doi.org/10.3389/fphys.2020.560802
  120. Appelhans B, Luecken L. Heart rate variability as an index of regulated emotional responding. Rev Gen Psychol. 2006;10(5):229-232. 
  121. Schwartz P, Vanoli E. Cardiac arrhythmias elicited by interaction between acute myocardial ischemia and sympathetic hyperactivity: A new experimental model for the study of antiarrhythmic drugs. J Cardiovasc Pharmacol. 1981;3(6):1251-1259. https://doi.org/10.1097/00005344-198111000-00012
  122. Baliki M, Chialvo D, Geha P, et al. Chronic pain and the emotional brain: Specific brain activity associated with spontaneous fluctuations of intensity of chronic back pain. J Neurosci. 2006;26(47):12165-12173. https://doi.org/10.1523/JNEUROSCI.3576-06.2006
  123. May A. Chronic pain may change the structure of the brain. Pain. 2008;137(1):7-15.  https://doi.org/10.1016/j.pain.2008.02.034
  124. Seminowicz D, Moayedi M. The dorsolateral prefrontal cortex in acute and chronic pain. J Pain. 2017;18(9):1027-1035. https://doi.org/10.1016/j.jpain.2017.03.008
  125. Sesa-Ashton G, Wong R, McCarthy B, et al. Stimulation of the dorsolateral prefrontal cortex modulates muscle sympathetic nerve activity and blood pressure in humans. Cereb Cortex Commun. 2022;3(2):tgac017. https://doi.org/10.1093/texcom/tgac017
  126. Qi X, Cui K, Zhang Y, et al. A nociceptive neuronal ensemble in the dorsomedial prefrontal cortex underlies pain chronicity. Cell Rep. 2022;41(11):111833. https://doi.org/10.1016/j.celrep.2022.111833
  127. Lawrence A, Jarrott B. Neurochemical modulation of cardiovascular control in the nucleus tractus solitarius. Prog Neurobiol.1996;48(1):21-53.  https://doi.org/10.1016/0301-0082(95)00034-8
  128. Kosinska M, Liebisch G, Lochnit G, et al. A lipidomic study of phospholipid classes and species in human synovial fluid. Arth Rheum. 2013;65(9):2323-2333. https://doi.org/10.1002/art.38053
  129. Alvarez-Garcia O, Rogers N, Smith R, Lotz M. Palmitate has proapoptotic and proinflammatory effects on articular cartilage and synergizes with interleukin-1. Arth Rheum. 2014;66(7):1779-1788. https://doi.org/10.1002/art.38399
  130. Fifth Joint Task Force of the European Society of Cardiology, European Association of Echolcardiography, European Association of Percutaneous Cardiovascular Interventions, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur J Prev Cardiol. 2012;19(4):585-667. National Institute for Health and Care Excellence (NICE). https://doi.org/10.1177/2047487312450228
  131. Cardiovascular disease: risk assessment and reduction, including lipid modification, 2016. London: National Institute for Health and Care Excellence (NICE). 18 July 2014; Last updated 10 February 2023. https://www.nice.org.uk/guidance/cg181
  132. Ludwick D, Doucette J. Adopting electronic medical records in primary care: lessons learned from health information systems implementation experience in seven countries. Int J Med Inf. 2009;1:78(1):22-31.  https://doi.org/10.1016/j.ijmedinf.2008.06.005
  133. Herrett E, Gallagher A, Bhaskaran K, et al. Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol. 2015;1:44(3):827-836.  https://doi.org/10.1093/ije/dyv098
  134. Torshin IYu, Lila AM, Zagorodniy NV, et al. Development of a verified osteoarthritis risk scale based on a cross-sectional study of clinical and anamnestic parameters and pharmacological anamnesis of patients. Modern Pharmacoeconomics and Pharmacoepidemiology. 2023;16(1):7-16. (In Russ.). https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.158
  135. Capewell S, O’Flaherty M. Rapid mortality falls after risk-factor changes in populations. Lancet. 2011;378(9793):752-753.  https://doi.org/10.1016/S0140-6736(10)62302-1
  136. Thompson P, Buchner D, Pina I, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: A statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation. 2003;107(24):3109-3116. https://doi.org/10.1161/01.CIR.0000075572.40158.77
  137. Naci H, Ioannidis J. Comparative effectiveness of exercise and drug interventions on mortality outcomes:Metaepidemiological study. BMJ. 2013;347:f5577. https://doi.org/10.1136/bmj.f5577
  138. Uthman O, van der Windt D, Jordan J, et al. Exercise for lower limb osteoarthritis: Systematic review incorporating trial sequential analysis and network metaanalysis. BMJ. 2013;347:f5555. https://doi.org/10.1136/bmj.f5555
  139. Sarvilina IV, Minasov TB, Lila AM, et al. On the efficacy of the parenteral form of highly purified chondroitin sulfate in the mode of perioperative preparation for total knee arthroplasty. RMJ. 2022;7:7-16. (In Russ.). https://www.rmj.ru/articles/revmatologiya/Ob_effektivnosti_parenteralynoy_formy_vysokoochischennogo_hondroitina_sulyfata_v_reghime_perioperacionnoy_podgotovki_k_endoprotezirovaniyu_kolennyh_sustavov/?ysclid=lhj01tej27841008410
  140. Schmidt M. Cardiovascular risks associated with nonaspirin non-steroidal anti-inflammatory drug use. Dan Med J. 2015;62:pii:B4987.
  141. Tomaselli G. Prevention of cardiovascular disease and stroke: meeting the challenge. JAMA. 2011;306(19):2147-2148. https://doi.org/10.1001/jama.2011.1668
  142. Vedanthan R, Seligman B, Fuster V. Global perspective on acute coronary syndrome: a burden on the young and poor. Circ Res. 2014;114(12):1959-1975. https://doi.org/10.1161/CIRCRESAHA.114.302782
  143. Teocharis A, Tsolakis I, Tzanakakis G, Karamanos N. Chondroitin sulfate as a key molecule in the development of atherosclerosis and cancer progression. Adv Pharmacol. 2006;53:281-295.  https://doi.org/10.1016/S1054-3589(05)53013-8
  144. https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.066  https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.066
  145. Yang W, Sun C, He S, et al. The efficacy and safety of disease-modifying osteoarthritis drugs for knee and hip osteoarthritis-systematic review and network meta-analysis. J Gen Intern Med. 2021;36(7):2085-2093. https://doi.org/10.1007/s11606-021-06755-z
  146. Kolasinski S, Neogi T, Hochberg M, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020;72(2):149-162.  https://doi.org/10.1002/acr.24131
  147. Kloppenburg M, Kroon F, Blanco F, et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019;78(1):16-24.  https://doi.org/10.1136/annrheumdis-2018-213826
  148. Smolen J, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685-699.  https://doi.org/10.1136/annrheumdis-2019-216655
  149. Bruyere O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49(3):337-350.  https://doi.org/10.1016/j.semarthrit.2019.04.008
  150. Falls in elderly and senile patients. Federation Health Ministry Clinical recommendations. 2020. (In Russ.). https://cr.rosminzdrav.ru/#!/recomend/1030
  151. Chronic pain in elderly and senile patients. Russian Federation Health Ministry Clinical recommendations. 2020. (In Russ.). https://cr.rosminzdrav.ru/#!/recomend/1033
  152. Clinical recommendations of the Ministry of Health of Russia «Gonarthrosis». 2021. (In Russ.). https://cr.minzdrav.gov.ru/recomend/667_1
  153. Clinical recommendations of the Ministry of Health of Russia «Coxarthrosis». 2021. (In Russ.). https://cr.minzdrav.gov.ru/recomend/666_1
  154. Iovu M, Dumais G, du Souich P. Anti-inflammatory activity of chondroitin sulfate. Osteoart Cart. 2008;16 Suppl 3:S14-18.  https://doi.org/10.1016/j.joca.2008.06.008
  155. Du Souich P, Garcia A,Verges J, Montell E. Immunomodulatory and anti-inflammatory effects of chondroitin sulphate. J Cell Mol Med. 2009;3(8A):1451-1463. https://doi.org/10.1111/j.1582-4934.2009.00826.x
  156. de Abajo F, Gil M, Garcia Poza P, et al. Risk of nonfatal acute myocardial infarction associated with non-steroidal antiinflammatory drugs, non-narcotic analgesics and other drugs used in osteoarthritis: a nested case-control study. Pharmacoepidemiol Drug Saf. 2014;23:1128-1138. https://doi.org/10.1002/pds.3617
  157. King D, Xiang J. Glucosamine/Chondroitin and Mortality in a US NHANES Cohort. J Am Board Fam Med. 2020;33(6):842-847.  https://doi.org/10.3122/jabfm.2020.06.200110
  158. Bell G, Kantor E, Lampe J, et al. Use of glucosamine and chondroitin in relation to mortality. Eur J Epidemiol. 2012;27(8):593-603.  https://doi.org/10.1007/s10654-012-9714-6
  159. Morrison L. Reduction of ischemic coronary heart disease by chondroitin sulfate. Angiology. 1971;22(3):165-174.  https://doi.org/10.1177/000331977102200308
  160. Morrison L, Enrick N. Coronary Heart Disease: Reduction of Death Rate By Chondroitin Sulfate. Angiology. 1973;24(5):269-287.  https://doi.org/10.1177/000331977302400503
  161. Nakazawa K, Murata K. Comparative study of the effects of chondroitin sulfate isomers on atherosclerotic subjects. Clinical Trial. Z Alternsforsch. 1979;34(2):153-159. 
  162. Mazzucchelli R, Rodrı´guez-Martı´n S, Garcı´a-Vadillo A, et al. Risk of acute myocardial infarction among new users of chondroitin sulfate: A nested case-control study. PLoS ONE. 2021;16(7):e0253932. https://doi.org/10.1371/journal.pone.0253932
  163. Melgar-Lesmes P, Sánchez-Herrero A, Lozano-Juan F, et al. Chondroitin Sulphate Attenuates Atherosclerosis in ApoE Knockout Mice Involving Cellular Regulation of the Inflammatory Response. Thromb. Haemost. 2018;118(7):1329-1339. https://doi.org/10.1055/s-0038-1657753
  164. Williams K, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995;15(5):551-561.  https://doi.org/10.1161/01.atv.15.5.551
  165. Adhikara I, Yagi K, Mayasari D, et al. Chondroitin Sulfate Nacetylgalactosaminyltransferase-2 Impacts Foam Cell Formation and Atherosclerosis by Altering Macrophage Glycosaminoglycan Chain. Arterioscler Thromb Vasc Biol. 2021 Mar;41(3):1076-1091. https://doi.org/10.1161/ATVBAHA.120.315789
  166. Bell J, Rhind S, Di Battista A, et al. Biomarkers of glycocalyx injury are associated with delayed cerebral ischemia following aneurysmal subarachnoid hemorrhage: a case series supporting a new hypothesis. Neurocrit Care. 2016;26(3):339-347.  https://doi.org/10.1007/s12028-016-0357-4
  167. Nuytemansa K, Ortelb T, Gomeza L, et al. Variants in chondroitin sulfate metabolism genes in thrombotic storm. Thromb Res. 2018;161:43-51.  https://doi.org/10.1016/j.thromres.2017.11.016
  168. Ye J, Esmon C, Johnson A. The chondroitin sulfate moiety of thrombomodulin binds a second molecule of thrombin. J Biol Chem. 1993;268(4):2373-2379.
  169. McGee M, Wagner W. Chondroitin Sulfate Anticoagulant Activity Is Linked to Water Transfer Relevance to Proteoglycan Structure in Atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23(10):1921-1927. https://doi.org/10.1161/01.ATV.0000090673.96120.67
  170. Moroudas A, Weinberg P, Parker K, Winlove C. The distribution and diffusion of small ions in chondroitin sulfate, hyaluronate and some proteoglycans solutions. Biophys Chem. 1988;32(2-3):257-270.  https://doi.org/10.1016/0301-4622(88)87012-1

Close metadata

Contact the author
Email
Message

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register


We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.